Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All tixagevimab/cilgavimab..
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 19% Improvement Relative Risk Tixagevimab/c.. for COVID-19  Din et al.  Prophylaxis Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19? Retrospective 64 patients in the USA (June 2020 - February 2022) Study underpowered to detect differences c19early.org Din et al., Hemasphere, August 2023 Favors tixagevimab/ci.. Favors control

COVID-19 infection among CAR-T cell therapy recipients: A single center experience

Aug 2023  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 64 COVID+ CAR-T cell therapy recipients, showing lower hospitalization with tixagevimab/cilgavimab prophylaxis in unadjusted results, without statistical significance.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, and BQ.1.1 Planas. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of hospitalization, 19.0% lower, RR 0.81, p = 0.77, treatment 5 of 23 (21.7%), control 11 of 41 (26.8%), NNT 20.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Din et al., 8 Aug 2023, retrospective, USA, peer-reviewed, 24 authors, study period June 2020 - February 2022.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperTixagev../c..All
### P1540 COVID-19 INFECTION AMONG CAR-T CELL THERAPY RECIPIENTS: A SINGLE CENTER EXPERIENCE Topic: 30. Infections in hematology (incl. supportive care/therapy)
Mohammad Ammad, Ud Din, Nayeon Oh, Aliyah Baluch, Olga Klinkova, Rod Quilitz, Melissa Alsina, Nelli Bejanyan, Omar Castaneda, Julio Chavez, Hany Elmariah, Ciara Freeman, Doris Hansen, Michael Jain, Farhad Khimani, Aleksandr Lazaryan, Hien Liu, Asmita Mishra, Leonel Ochoa, Lia Perez, Joseph Pidala, Bijal Shah, Taiga Nishihori, Frederick Locke, Rawan Faramand
Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit